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Case Report
Perampanel-Induced Cataplexy in a Young Male
with Generalized Epilepsy
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Perampanel (Fycompa) is a newer anti-epileptic drug believed to exert its effects in the
central nervous system by inhibiting post-synaptic glutamate receptors. However, the precise therapeutic mechanism is unknown. The most common neuropsychiatric side effect is
affective dysregulation; there are also reports of psychosis. We describe a 32 year old African
American male with recurring generalized tonic-clonic (GTC) seizures, who presented to
our hospital with onset of mood lability for several months, after Perampanel was added
to his antiepileptic medications. Perampanel administration was temporarily withheld, and
subsequently on restarting, noted to be coincident with neuropsychiatric symptomatology,
including motor weakness in emotional contexts. The mechanisms underlying cataplexy are
complex and, in our patient, most likely induced by an interaction between Perampanel and
the wakeful inhibition of the sublaterodorsal nucleus projections.
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Introduction

Perampanel (Fycompa) is an anticonvulsant
agent approved by the US Food and Drug Administration (FDA) in 2012 as adjunctive therapy for the treatment of partial-onset seizures
with or without secondary generalized seizures
in patients aged 12 years or older.1 Perampanel
is the first medication to be specifically designed with glutamate inhibition as its primary
mechanism of action.2 The alleged mechanism
of action involves non-competitive selective
antagonism at the postsynaptic ionotropic
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor.1 By acting as a
non-competitive inhibitor, perampanel allows
glutamate to bind to its receptor, but inhibits
the normal excitatory physiologic response.3
The most common side effects of perampanel include dizziness, somnolence, headache,
fatigue, falls, ataxia, nausea, vertigo and back
pain.1 Adverse psychiatric effects, including

potential for affective changes, may possibly
occur at a greater rate than some the older
antiseizure agents. Phase III data documented
irritability at dose-dependent rates of 3% with
placebo, and 4%, 7% and 12% with 4, 8 and 12
mg/day respectively.2 Per the FDA package
insert, “in the controlled partial-onset seizure
clinical trials, hostility- and aggression-related
adverse reactions occurred in 12% and 20% of
patients randomized to receive perampanel at
doses of 8 mg and 12 mg per day, respectively, compared to 6% of patients in the placebo
group.”2 Homicidal ideation and/or threats were
reported in 0.1% of the 4138 participants.1
We believe this case is the first reported of
cataplexy related to perampanel use.

Case Presentation

A 32-year-old African American man with a
history of HIV, generalized tonic-clonic seizure
disorder, depression and anxiety presented to a
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hospital emergency department with worsening memory lapses and mood lability episodes.
The most recent symptoms included bouts of
laughter starting three days prior to presentation. He was taking levetiracetam 1000mg,
carbamazepine XR 400mg, and perampanel
10mg, all once daily, for recurrent generalized
tonic-clonic seizures. Durations of use were:
levetiracetam, 2 years; carbamazepine, over 11
years; and perampanel, 7-8 months. The patient’s symptoms began about 7-8 months before the ED presentation, starting with heightened fearfulness, followed by paranoia akin to
PTSD, and then progressing to include memory
loss and what was thought to be mood lability
on evaluation in the emergency department.
He denied previous similar symptoms, and
there was no known family history of mental
illness or narcolepsy per the family. His symptoms resulted in extreme social impairment;
the patient had given up living independently
and had moved back in with his parents so they
could help care for him.

Hospital Course

The patient was admitted to the inpatient psychiatric unit for further evaluation and treatment of mood lability and abnormal behavior.
As a probe into the etiology of his lability, it
was noted during direct history and mental
status examination that the lability was able
to be manipulated by changing the topic from
neutral to sad or humorous, and back to neutral, with congruent abrupt affect changes in
the patient. Additionally, the patient’s episodes
of severe laughing or crying involved loss of
muscle tone, resulting in his head initially falling
to the side or front; he also fell to the floor
several times. These findings were consistent
with a clinical diagnosis of cataplexy. An EEG
showed no presence of temporal lobe or other
seizure activity, despite emotional changes
precipitated by changes in conversational tone
by the technician during the test.
Perampanel and carbamazepine were not given
at admission, as the carbamazepine level was
supratherapeutic and perampanel was non-formulary and not initially available. The cataplexy
episodes resolved after 2 days, but on day 3,
the patient then suffered several seizures and
was transferred to a medical unit. On hospital
day 4, he did not display cataplexy or lability of
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any kind. Per family’s report, the patient had
good seizure control on carbamazepine monotherapy. Poor compliance resulted in recurrent
seizures and additional anticonvulsants added
to his medications. The patient was restarted
on all of his anti-epileptics with a plan to taper
perampanel first if stable, followed by levetiracetam. Several hours after receiving a dose of
perampanel, the patient became confused, and
had visual hallucinations and severe agitation
requiring physical restraints. New periods of
emotional lability and muscle weakness precipitated by emotional contexts during social
communication re-emerged, consistent with
reduplicated cataplexy. Perampanel was again
discontinued and the patient was observed
for two additional days, during which time his
memory improved, and he did not display any
further cataplexy episodes, agitation, or endorse visual hallucinations.

Discussion

Cataplexy is defined as an emotionally triggered paralysis or sudden involuntary loss of
muscle tone with preserved consciousness; it is
a pathognomonic symptom of narcolepsy.4,5,6,7
Cataplexy presents alone, as well as comorbid
with narcolepsy, Parkinson’s disease, multiple
sclerosis, head trauma, encephalitis and drop
attack-types of seizures.6 Most cataplexy episodes are triggered by strong positive emotions such as laughter. Reported causes include
drug-induced cataplexy, through the rapid
withdrawal of tricyclic antidepressants6 or lamotrigine.8 The prevalence of isolated cataplexy
is unknown, but the prevalence of cataplexy in
those with excessive daytime somnolence has
been reported as up to 29%.6
The differential diagnosis of cataplexy includes: migraine headaches, bradycardia with
presyncope, delayed sleep-phase syndrome,
temporal or partial complex/akinetic seizures,
Niemann-Pick Type C disease, Coffin-Lowry
syndrome, pontomedullary lesions, conversion
disorder, malingering and chronic psychotic
disorder.4,5
The exact mechanism behind cataplexy is still
unknown, but it is hypothesized that orexin
(also known as hypocretin), plays a major role.
Orexin A and orexin B (also known as hypocretin 1 and hypocretin 2, respectively) are neuro-
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Figure 1. Suggested pathway for normal muscle tone. During normal wake periods in noncataleptic individuals, orexin stimulation of the vlPAG/LPT nuclei and monoaminergic centers, leads
to adequate inhibition of the sublaterodorsal nuclei and hence, maintenance of normal muscle
tone. Adapted with permission from Burgess et al.18 vlPAG: ventrolateral periaqueductal grey, LPT:
lateral pedunculopontine tegmentum, NE: norepinephrine, 5HT: 5-hydroxytryptamine (Serotonin),
SLD: sublaterodorsal nuclei. Solid line: stimulation; Dashed line: inhibition; line thickness correlates with strength
peptides synthesized in the lateral hypothalamus that have wide excitatory projections to
the nuclei in the arousal system.9-11,13-15 The orexins promote wakefulness with innervation and
excitation of key nuclei in both the dorsal and
ventral aspects of the arousal system.13,19 They
also play a stabilizing role, maintaining consolidated sleep and wakeful periods. Patients
suffering from narcolepsy with cataplexy have
been shown to be deficient in orexin signaling,
with loss of almost 90% of their orexin-producing neurons.13,18
Cataplexy is thought to be the result of intrusion of incomplete REM into wakefulness. Activation of the same brain regions occur in both
REM sleep atonia and cataplexy.18 A comprehensive review of the complex circuitry involved
in sleep regulation is beyond the scope of this
report. Salient points are discussed below.
The sublaterodorsal nucleus (SLD), a group of
neurons in the caudal pons, plays a significant
role in REM sleep.4,11 Glutamatergic neurons in
the SLD project to the ventromedial medulla,
stimulating GABAergic and glycinergic interneurons, resulting in the atonia seen during
REM sleep. For purposes of this discussion, the
SLD can be considered a gatekeeper to muscle
atonia observed in REM sleep and cataplectic
attacks.

The SLD receives inhibitory inputs from
monoaminergic neurons and, the ventrolateral
periaqueductal grey matter (vlPAG) and the
lateral pedunculopontine tegmentum (LPT),
and excitatory inputs from the central nucleus
of the amygdala.4,11,13,14,16,18,19 The amygdala, a key
region for processing emotional stimuli, also
sends inhibitory projections to the vlPAG/
LPT.5,18 During normal wake periods, the vlPAG/
LPT send inhibitory projections to the SLD,
thereby opposing SLD mediated muscle
atonia.18 (Figure 1) However, in cataplexy,
unopposed projections from the amygdala to
the SLD reduce muscle tone when processing
positive emotional stimuli, resulting in
muscle atonia and postural failure. In healthy
individuals, the propensity of these projections
to cause cataplectic atonia is prevented by an
increase in the hormone orexin during positive
emotions, as well as the monoaminergic and
GABAergic vlPAG/LPT inhibition of the SLD
discussed above.4,12,16,17,18,20,21 (Figure 2) More
broad arousal system networks not known
to be involved in cataplexy include activating
projections to the cortex, involving neuronal
pathways from the brainstem reticular
formation, thalamus, posterior hypothalamus,
and basal forebrain.19
Treatment of traditional cataplexy has centered
on the use of antidepressants. The first antidepressants reported as efficacious were tricyclic
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Figure 2. Suggested pathway for muscle atonia. In cataplectic patients, it is hypothesized that
processing of positive (and some negative) stimuli by the CeA, inhibits the vlPAG/LPT and stimulates the SLD, overcoming the vlPAG/LPT and monoaminergic inhibition. This leads to REM-type
atonia during wakefulness and symptoms of cataplexy. Adapted with permission from Burgess
et al.18 vlPAG: ventrolateral periaqueductal grey, LPT: lateral pedunculopontine tegmentum, NE:
norepinephrine, 5HT: 5-hydroxytryptamine (Serotonin), SLD: sublaterodorsal nuclei, CeA: contral
nucleus of the amygdala. Solid line: stimulation; Dashed line: inhibition; line thickness correlates
with strength
antidepressants.4 The most commonly used
tricyclic antidepressants for cataplexy have
been imipramine, protryptiline, and clomipramine. Selective serotonin reuptake inhibitors
have been also been used, but relatively high
doses are required which results in greater
adverse effects.5 Low to moderate doses of
SNRI antidepressants may be of most benefit
with the lowest side effect profiles, although
there is a lack of controlled evidence.3,4 Sodium oxybate is another drug that has shown
efficacy in treating cataplexy and is approved
by the Food and Drug Administration and the
European Medicines Agency for this indication.5
Sodium oxybate is the sodium salt of β-hydroxybutyrate. Its exact mechanism of efficacy
is unknown but may involve GABA-B receptors,
causing an activation of slow-wave sleep.5 The
drug unfortunately is expensive, making SNRI
antidepressants still the best option for most
individuals.
This case is believed to be the first reported of
perampanel-induced cataplexy. The pathophysiology is unknown but likely involves the glutamate pathway. It is unlikely that the cataplexy
seen in our patient resulted from perampanel-inhibiting, orexin-secreting neurons of the
lateral hypothalamus or action as an orexin
receptor antagonist, as the reduction of diffuse
orexin innervation of the arousal and sleep-in-
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ducing systems would result in some form of
sleep disorder such as narcolepsy, hypnagogic
or hypnopompic hallucinations, sleep paralysis
or REM sleep behavior disorder. Our patient
had no reported or observed complaints of
sleep disorder.
We posit that in our patient, perampanel was
reducing the wakeful inhibition of the SLD,
allowing the amygdala to induce atonia. If perampanel works only by inhibiting AMPA receptors in the brain,3 then a possible mechanism of
cataplexy in our patient could be an inhibition
of the vlPAG/LPT GABAergic or LC/DR monoaminergic projections to the SLD. Given the
absence of any sleep disorder, the latter is less
likely and a perampanel-vlPAG/LPT interaction
is more likely.

Conclusion

Perampanel-induced cataplexy should be
included in the differential diagnosis of perampanel-treated patients presenting with lability
concerns. As the use of perampanel increases,
more neurologists, primary care providers, hospitalists and psychiatrists may see more epileptic patients with perampanel-related psychiatric-domain adverse effects, such as irritability
or aggression, as well as memory loss, as in
our patient. Increased awareness of cataplexy
and other psychiatric presentations as adverse
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effects of perampanel will lessen the possibility
that those affected could be inappropriately
treated with antipsychotics or benzodiazepines
for what may be mistaken for a mood or other
organic mental disorder.

Acronyms

DR: dorsal and median raphe nuclei (monoaminergic-5-HT)
LC: locus coeruleus (monoaminergic-NE)
TMN: Tuberomamillary nuclei (monoaminergic-HA)
LPT: Lateral pontine tegmentum
vlPAG: ventrolateral Periaqueductal gray matter
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